MTEC

Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command's (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract was awarded through Medical Technology Enterprise Consortium (MTEC) for prototype solutions that prevent combat wound infections following blast injuries and burns.

This project, titled “Augmented Neurophysiology of Sleep and Performance Readiness,” is part of the Medical Technology Enterprise Consortium, a collaboration between industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command and other Department of Defense agencies in the biomedical sciences to protect, treat, and optimize the health and performance of military personnel.

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology Enterprise Consortium (MTEC).

Researchers at the University of Alabama at Birmingham will investigate the usefulness of a new non-invasive method to measure the expansion of hematomas in the brain. This project is funded by the Combat Casualty Care Research Program’s Neurotrauma Program at the US Army Medical Research and Development Command via the Medical Technology Enterprise Consortium.

The $2.8 million award issued through the Medical Technology Enterprise Consortium is for the first year of what the research team anticipates will be a multiyear grant from the U.S. Army. The primary goal is to noninvasively measure and modulate the flow of cerebrospinal fluid as it circulates through the brain and clears waste.

Mitochon Pharmaceuticals today is pleased to announce the receipt of a $500,000 grant in conjunction with the University of Kentucky for “Advancement of Drugs for the Treatment of Repeated Mild Traumatic Brain Injury (mTBI)” through a joint funded program by an Alzheimer’s Disease group, BrightFocus Foundation and a military focused foundation, Medical Technology Enterprise Consortium (MTEC).

The U.S. Army Medical Research and Development Command (USAMRDC) has awarded Expression Networks a phase 2 award in support of the Medical Technology Enterprise Consortium's (MTEC) National Emergency Telecritical Care Network (NETCCN) Project.

Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, today announced its selection by the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program to receive $2.43 million from the U.S. Department of Defense to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment. The award was issued through Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.